In final updated guidance published today NICE recommends a number of drugs called biological disease modifying drugs (DMARDs) as options for treating severei rheumatoid arthritis which has not ...

The recommendation is the first step toward making the therapy widely available to patients in England and Wales. Sanofi’s sarilumab, approved earlier this year by both FDA and European regulators to ...

The National Institute for Health and Clinical Excellence (NICE) has issued final guidance rejecting the use of Bristol-Myers Squibb's Orencia (abatacept) as a second-line treatment for rheumatoid ...

With its Allergan merger likely in the final stages, AbbVie is placing its hopes in a pair of home-grown drugs to help weather biosimilar attacks against Humira. One of those, JAK inhibitor Rinvoq, ...

The UK medicines cost-effectiveness watchdog has recommended Eli Lilly’s JAK inhibitor Olumiant as a treatment for some people with rheumatoid arthritis (RA). In draft guidance, the National Institute ...